Israel Englander Allovir, Inc. Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.4 - $1.01 $100,407 - $253,528	-251,018 Reduced 7.64%	3,033,782 $1.27 Million
Q3 2024 Nov 14, 2024	SELL	$0.7 - $0.82 $7,650 - $8,961	-10,929 Reduced 0.33%	3,284,800 $2.66 Million
Q2 2024 Aug 14, 2024	BUY	$0.72 - $0.82 $254,247 - $289,559	353,121 Added 12.0%	3,295,729 $2.37 Million
Q1 2024 May 15, 2024	SELL	$0.64 - $0.78 $615,296 - $749,892	-961,401 Reduced 24.63%	2,942,608 $2.24 Million
Q4 2023 Feb 14, 2024	BUY	$0.68 - $2.39 $2.51 Million - $8.82 Million	3,689,279 Added 1718.1%	3,904,009 $2.65 Million
Q2 2023 Aug 14, 2023	BUY	$3.17 - $5.82 $462,249 - $848,672	145,820 Added 211.61%	214,730 $730,000
Q1 2023 May 15, 2023	BUY	$3.94 - $7.05 $165,606 - $296,325	42,032 Added 156.38%	68,910 $272,000
Q4 2022 Feb 14, 2023	BUY	$4.7 - $9.98 $126,326 - $268,242	26,878 New	26,878 $138,000

730K

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $913M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.